Quantcast

Latest Tumor markers Stories

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-03 08:32:58

Prostate Cancer Awareness Month in September Promotes Importance of Early Detection to Save Men's Lives MELVILLE, N.Y., Sept. 3, 2014 /PRNewswire/ -- Henry Schein Cares, the global corporate social responsibility program of Henry Schein, Inc., and the Large Urology Group Practice Association (LUGPA) have partnered again this year to raise awareness among families across the country about the importance of putting prostate cancer check-ups on the calendar for the men in their lives....

2014-08-19 16:29:12

GILBERT, Ariz., Aug. 19, 2014 /PRNewswire/ -- A cutting-edge research study at Banner MD Anderson Cancer Center is testing the safety and effectiveness of a new investigational drug that, when combined with chemotherapy, may make a major difference in treating breast cancer in patients who carry harmful mutations on either the BRCA1 or BRCA2 genes. The Brocade Study will enroll patients with hereditary breast cancer that is metastatic, meaning it has spread to other parts of the...

Gene Increases Risk Of Developing breast Cancer To One In Three By Age 70
2014-08-08 03:08:44

University of Cambridge Breast cancer risks for one of potentially the most important genes associated with breast cancer after the BRCA1/2 genes are today reported in the New England Journal of Medicine. Women with mutations in the PALB2 gene have on average a one in three chance of developing breast cancer by the age of seventy. In a study run through the international PALB2 Interest Group a team of researchers from 17 centers in eight countries led by the University of Cambridge...

2014-06-26 08:27:43

- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast...

2014-06-25 23:14:27

AllMed webinar provides in-depth review of the latest in standard of care for the genetic testing of breast and ovarian cancer. Portland, Oregon (PRWEB) June 25, 2014 Advances in genetic testing technology have improved detection rates for BRCA1 and BRCA2 mutations in individuals who are at high risk for breast and ovarian cancer, but some mutations are missed with standard genetic testing. During a recent AllMed webinar, Dr. Della Howell, board-certified hematologist-oncologist,...

2014-06-11 08:31:25

LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cancer Diagnostic Testing World Marketshttp://www.reportbuyer.com/pharma_healthcare/diagnostics/cancer_diagnostic_testing_world_markets.html Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs...

2014-06-06 08:24:52

Initial clinical experience with 89Zr-labeled anti-PSMA minibody presented LOS ANGELES, June 6, 2014 /PRNewswire/ -- ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand...

2014-05-27 08:27:46

-- High calibre German consulting company appointed to assist CE Mark registration process SYDNEY, May 27, 2014 /PRNewswire/ -- Australian biotechnology company Minomic International Limited will register its MiStat(TM) ELISA prostate cancer test for CE Mark approval in the latter part of 2014. Achieving CE approval will be a key commercial milestone for the company, allowing it to sell and market its early detection diagnostic technology in the 33 member countries within the...

2014-05-16 12:27:55

The Lipo 7 product is a perfect alternative to the HCG injection product for those preferring vitamins, minerals and amino acids over the hcg injections. NEW HAVEN, Conn., May 16, 2014 /PRNewswire-iReach/ -- Lipotropic Injections are weight loss injections made of natural ingredients like vitamins, minerals and amino acids that assist in metabolizing and burning fats stored in the body. These nutrients are typically given in concentrated doses not typically found in just one meal...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related